-+ 0.00%
-+ 0.00%
-+ 0.00%

Ligand Pharm's Partner Pelthos Therapeutics Commercially Launches ZELSUVMI Topical Gel 10.3%, FDA-Approved At-Home Treatment For Molluscum Contagiosum

Benzinga·07/10/2025 12:09:22
Listen to the news

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE:PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum. The Company has earned a $5 million milestone payment from Pelthos following the commercial launch of ZELSUVMI.

Following the completion of the merger between Pelthos Therapeutics and Channel Therapeutics in July 2025, Ligand now owns 56% of Pelthos. Additionally, under the terms of the license agreement with Pelthos, Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI and up to an additional $5 million in commercial sales milestones.